Hypoxia-inducible factor-2α (HIF-2α) inhibitor belzutifan in von Hippel-Lindau (VHL) disease–associated neoplasms: 5-year follow-up of the phase 2 LITESPARK-004 study.
Hypoxia-inducible factor-2α (HIF-2α) inhibitor belzutifan in von Hippel-Lindau (VHL) disease–associated neoplasms: 5-year follow-up of the phase 2 LITESPARK-004 study.
Tobias Else, Eric Jonasch, Benjamin Louis Maughan, Ramaprasad Srinivasan et al.
Citations
2 citations
Journal
Journal of Clinical Oncology
Topics
Cancer, Hypoxia, and Metabolism
Field-Weighted Citation Impact (FWCI)
1.87
article
Hypoxia-inducible factor-2α (HIF-2α) inhibitor belzutifan in von Hippel-Lindau (VHL) disease–associated neoplasms: 5-year follow-up of the phase 2 LITESPARK-004 study.
Tobias Else, Eric Jonasch, Benjamin Louis Maughan, Ramaprasad Srinivasan, Jodi K. Maranchie, Othon Iliopoulos, Ane Bundsbæk Bøndergaard Iversen, Jerry Cornell, Stéphane Oudard, Vivek Narayan, Rodolfo F. Perini, Yanfang Liu, W. Marston Linehan, Katy Beckermann
article en
2 citations
Abstract
No abstract available for this paper.
Publication Tag
Journal of Clinical OncologyVol. 43(16_suppl)
Institutions
Merck & Co., Inc., Rahway, NJ, USA (United States) (US), National Institutes of Health (US), The University of Texas MD Anderson Cancer Center (US), Harvard University (US), Vanderbilt University (US), Université Paris Cité (FR), University of Utah (US), University of Michigan (US), Hospital of the University of Pennsylvania (US), Huntsman Cancer Institute (US), Aarhus University Hospital (DK), Massachusetts General Hospital (US), Assistance Publique – Hôpitaux de Paris (FR), Hôpital Européen Georges-Pompidou (FR), University of Pittsburgh Medical Center (US), National Cancer Institute (US)
Ask Laika to Summarize, Analyze, and Connect papers live on the map.
Summarize Papers & Methodologies
Extract key findings, datasets, and comparative methods across publications.
Benchmark Rankings & Visual Analytics
Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.
Connect Distant Disciplines
Bridge topological clusters on the map to find hidden collaborative intersections.
Hypoxia-inducible factor-2α (HIF-2α) inhibitor belzutifan in von Hippel-Lindau (VHL) disease–associated neoplasms: 5-year follow-up of the phase 2 LITESPARK-004 study. — Tobias Else, Eric Jonasch, et al. · Journal of Clinical Oncology (2025) | TGRS Research Map | TGRS